Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin/Lilly’s Once-Weekly Exenatide Wins Head-To-Head Over Byetta

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms expect to file NDA by end of first half 2009.

You may also be interested in...



Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s

Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.

Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s

Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.

Amylin Halts Development Of Symlin With Approved Appetite Suppressants

The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel